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2720Objectives: The study objective was to identify the predictors of outcomes in a contemporary cohort of patients
from the Reduction in cardiovascular Events by acaDesine in patients undergoing CABG (RED-CABG) trial.
Despite the increasing risk profile of patients who undergo coronary artery bypass grafting, morbidity and
mortality have remained low, and identification of the current predictors of adverse outcomes may permit
new treatments to further improve outcomes.
Methods: The RED-CABG trial was a multicenter, randomized, double-blind, placebo-controlled study that deter-
mined that acadesine did not reduce adverse events in moderately high-risk patients undergoing nonemergency
coronary artery bypass grafting. The primary efficacy end point was a composite of all-cause death, nonfatal stroke,
or the need for mechanical support for severe left ventricular dysfunction through postoperative day 28. Logistic
regressionmodelingwith stepwisevariable selection identifiedwhichprespecifiedbaseline characteristicswere asso-
ciated with the primary outcome. A second logistic model included intraoperative variables as potential covariates.
Results: The 4 independent preoperative risk factors predictive of the composite end point were (1) a history of
heart failure (odds ratio, 2.9); (2) increasing age (odds ratio, 1.033 per decade); (3) a history of peripheral
vascular disease (odds ratio, 1.6); and (4) receiving aspirin before coronary artery bypass grafting (odds ratio,
0.5), which was protective. The duration of the cardiopulmonary bypass (odds ratio, 1.8) was the only
intraoperative variable that contributed to adverse outcomes.
Conclusions: Patients who had heart failure and preserved systolic function had a similar high risk of adverse
outcomes as those with low ejection fractions, and new approaches may mitigate this risk. Recognition of
patients with excessive atherosclerotic burden may permit perioperative interventions to improve their
outcomes. The contemporary risks of coronary artery bypass grafting have changed, and their identification
may permit new methods to improve outcomes. (J Thorac Cardiovasc Surg 2014;148:2720-6)e Division of Cardiac Surgery,a Toronto General Hospital and University of
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BM ¼ bone marrow
CABG ¼ coronary artery bypass grafting
CVD ¼ cerebrovascular disease
EF ¼ ejection fraction
Hct ¼ hematocrit
HF ¼ heart failure
Hgb ¼ hemoglobin
MI ¼ myocardial infarction
PCI ¼ percutaneous coronary intervention
POD ¼ postoperative day
PVD ¼ peripheral vascular disease
RED-CABG ¼ Reduction in cardiovascular Events
by acaDesine in patients undergoing
CABG
SLVD ¼ severe left ventricular dysfunction
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DCoronary artery bypass grafting (CABG) has evolved
remarkably over the last decade. Recent studies have more
clearly defined the current indications for CABG distinct
from percutaneous coronary interventions (PCIs).1,2
Because of the increasing complexity and disability of
patients who are referred for CABG rather than PCI,3,4 the
predictors of the current results of CABG must be
periodically updated to account for the changes in patient
characteristics and contemporary surgical techniques.
To determine the predictors of current outcomes, we
evaluated the results in a recently completed multicenter
trial of 3080 patients undergoing CABG (Reduction in
cardiovascular Events by acaDesine in patients undergoing
CABG [RED-CABG] trial).5 The goal of this report is to
identify the current predictors of CABG outcomes to target
interventions to improve the results.6,7
We first determined the preoperative predictors and then
evaluated intraoperative variables to assess their added
value to predict postoperative adverse outcomes. Innovative
approaches to preoperative preparation and new intraopera-
tive techniques may improve outcomes in the future.
METHODS
Study Design and Patient Populations
The RED-CABG trial (clinicaltrials.gov Identifier: NCT00872001)
was a multicenter, randomized, double-blind, placebo-controlled,
parallel-group study designed to evaluate the ability of acadesine to reduceThe Journal of Thoracic and Carthe incidence of ischemia/reperfusion injury in moderate- to high-risk
subjects undergoing nonemergency CABG. All patients in the study
underwent CABG with cardiopulmonary bypass, had an increased risk of
postoperative adverse events, and met all of the criteria for trial entry.
The primary results of the trial were recently reported.5 The baseline
characteristics are provided in Table E1. Patients requiring urgent,
emergency, or salvage CABG were excluded. In addition, patients with
preoperative renal dysfunction (serum creatinine level >2 mg/dL or
180 mmol/L) were specifically excluded to avoid complications associated
with acadesine treatment.
Primary End Point
The primary efficacy end point was a composite of the occurrence of any
of the following during surgery or through postoperative day (POD) 28:
all-cause death, nonfatal stroke, or the need for mechanical support for
severe left ventricular dysfunction (SLVD). Nonfatal stroke was defined
as an acute focal neurologic deficit of sudden onset that was not reversible
within 24 hours and was not due to an identifiable nonvascular cause
accompanied by clear evidence of a new stroke on brain imaging
(computed tomography scan or magnetic resonance imaging). SLVD was
defined as the new use of a mechanical circulatory assist device, such as
an intra-aortic balloon pump or a ventricular assist device, during or after
CABG for at least 1 hour for the treatment of low cardiac output.8
Indications for using circulatory assist devices were determined by the
attending physician on the basis of his/her clinical judgment and included
cardiogenic shock, difficulty weaning from cardiopulmonary bypass,
refractory left ventricular failure, refractory ventricular arrhythmias, and
other indications that the investigators deemed necessary for treatment of
low cardiac output syndrome. All efficacy end points except all-cause death
were adjudicated by an independent, blinded clinical events committee.
Secondary End Points
The key secondary efficacy end point was the first occurrence of any
component of the composite end point occurring during and after CABG
surgery through POD 28.
Statistical and Analytic Plans
Logistic modeling was used to assess the prognostic factors for the
primary composite end point of the trial through POD 28. Candidate
variables for this model were selected on the basis of clinical importance
and included age, gender, ejection fraction (EF), extent of coronary artery
disease, preoperative evidence of cerebrovascular disease (CVD) (prior
stroke, transient ischemic attack, or other CVD; carotid stenosis; carotid
endarterectomy; or PCI), history of peripheral vascular disease (PVD) (prior
PVD, claudication, or peripheral arterial revascularization), previous coro-
nary intervention (CABG or PCI), history of heart failure (HF), previous
myocardial infarction (MI), hypertension, hyperlipidemia, diabetes melli-
tus, history of cigarette smoking, history of atrial fibrillation/flutter, anemia
(hemoglobin [Hgb]<11 g/dL or hematocrit [Hct]<33% before the start
of CABG), and the preoperative use of clopidogrel or aspirin. Restricted
cubic splines were used to examine the conformity of continuous variables
with the assumption of a linear relationship to the outcome. Principle
components analysis was used in an effort to consolidate information
frommultiple sources (eg, for history of PVD). A simple composite indica-
tor was found to be adequate for these categories.
Stepwise selection of covariates from the candidate list of preoperative
variables was performed with model inclusion and exclusion criteria of
P ¼ .05. Wald chi-square P values and odds ratios with 95% confidence
intervals were used to summarize the risk associated with the final model
covariates. Figures of the adjusted relationship of each factor in the final
preoperative model were generated by calculating the predicted probability
and 95% confidence interval of each outcome, assuming the median value
for all other factors.diovascular Surgery c Volume 148, Number 6 2721
TABLE 1. Composite of death, severe left ventricular dysfunction, or
nonfatal stroke to postoperative day 28: Independent predictors of the
primary composite outcome: All-cause death, need for mechanical
support for severe left ventricular dysfunction, or nonfatal stroke to
postoperative day 28
Analysis of maximum likelihood estimates
Parameter Odds ratio
95%Wald
confidence limits P value
History of HF 2.905 2.006 4.208 <.0001
Age (per 10-y increase) 1.033 1.013 1.053 .0011
History of PVD 1.621 1.115 2.357 .0115
Aspirin before CABG 0.501 0.328 0.766 .0014
CABG, Coronary artery bypass grafting; HF, heart failure; PVD, peripheral vascular
disease.
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DIn a second stage of the modeling process, intraoperative variables were
included along with the significant preprocedure covariates previously
selected as potential covariates for a parsimonious model of the primary
outcome (a composite of death, SLVD, or nonfatal stroke at POD 28).
Stepwise selection was used, using a selection and retention criteria of
P ¼ .05. The candidate covariates that were considered were age, history
of PVD, history of HF, aspirin use before CABG, last Hgb and Hct
measurements before CABG end, transfusion of whole blood or packed
red blood cells during the CABGprocedure, cardioplegia type, temperature
and direction (antegrade, retrograde, or combined), number of nonarterial
grafts, number of arterial grafts, duration of crossclamp (in hours), duration
of CPB (in hours), and atrial fibrillation before completion of the CABG
procedure from the electrocardiogram recordings. Statistical analyses
were performed by the coordinating center (Duke Clinical Research
Institute, Durham, NC) using SAS version 9.2 (SAS Institute Inc,
Cary, NC).RESULTS
This multicenter trial provides an overview of current
techniques of CABG at multiple institutions in North
America and Europe. Table E1 lists the countries where
CABG cases were enrolled in this study. Neither country
nor continent was predictive of adverse outcomes.FIGURE 1. Adjusted association between age and primary composite end
point. The figure plots increasing age against the estimated event rates for
the primary composite outcome, assuming the median value of history of
HF (no) and history of PVD (no) and use of aspirin before CABG (yes).
Increasing age was associated with an increased risk of the composite
outcome. CI, Confidence interval.Preoperative Predictors of Outcome After Coronary
Artery Bypass Grafting
From the patient’s perspective, the most important
outcome of CABG is event-free survival. The primary
composite end point of this trial was designed to represent
this perspective. The primary composite end point of this
trial included all-cause death, nonfatal stroke, or need for
mechanical support for SLVD through POD 28. Table E2
outlines the factors evaluated to determine the independent
predictors. The statistically significant preoperative
predictors of adverse primary outcome (Table 1) included
a history of HF, a history of PVD, and age, whereas aspirin
use before CABG was protective.
The influence of age on the primary outcome is depicted
in Figure 1, assuming the median value of history of HF or
PVD (both no) and use of aspirin before CABG (yes).
Increasing age was associated with an increased risk of
the composite outcome. The estimated composite event
rate for patients with and without a history of HF is
presented in Figure 2, assuming an age of 66 years, no
history of PVD, and aspirin before CABG. HF increased
the risk of the composite outcome (Figure 2). Similar results
were seen in the adjusted bar graph of patients with and
without PVD (Figure 3) and those not receiving aspirin
before CABG (Figure 4).
A history of HF was a more powerful predictor of the
composite end point than EF. Among the 404 patients
with HF, 260 had an EF of 30% or greater, and among
the 298 patients with an EF less than 30%, 154 did not
have a history of HF. The patients with HF with an EF of
30% or greater had a greater incidence of diabetes mellitus
and hypertension than patients with no HF or patients with2722 The Journal of Thoracic and Cardiovascular SurHF and an EF less than 30%, suggesting that these patients
may have had diastolic dysfunction. The patients with a low
EF who did not have HF had the lowest incidence of
diabetes and PVD.
PVD may have contributed to adverse outcomes because
of an increased atherosclerotic burden. The majority of
patients with PVD (355/483 [73%]) had claudication or
previous vascular interventions. Patients with PVD were
more likely to be smokers (79%) than patients without
PVD (59%).
The rate of the composite outcome was approximately
twice as high among patients not receiving aspirin
(8.72%) compared with patients receiving aspirin
(4.58%) preoperatively. More of the patients taking aspirin
preoperatively also were receiving clopidogrel (40% vs
23%), and fewer of the patients taking aspirin were anemic
(Hgb <11 or Hct <33) before surgery (16% vs 18%).
Clopidogrel was considered as a potential covariate in our
model but was not found to be statistically significantgery c December 2014
FIGURE 2. Adjusted association between HF and primary composite end
point. Estimated event rates for patients with and without a history of HF,
assuming an age of 66 years, no history of PVD, and aspirin before CABG.
The risk of the composite outcome was greater in patients with HF.
FIGURE 4. Adjusted association between preoperative aspirin and
primary composite end point. The estimated event rates for patients with
and without preoperative aspirin treatment, assuming an age of 66 years
and no history of HF or PVD. The risk of the composite outcomewas lower
for those who were taking aspirin preoperatively.
Weisel et al Acquired Cardiovascular Diseaseunadjusted or after adjustment for other covariates,
including aspirin use.
Tables 2-4 summarize the performance of the
preoperative predictors of the composite end point when
applied to the individual components of death, stroke, and
SLVD, respectively. The 4 preoperative predictors of the
composite outcome selected by stepwise methods also
were significant in modeling early (28-day) mortality.
When applied to the stroke component, only the covariates
age and a history of PVD were significant. Of note, PVD
was more predictive than a history of CVD.A
C
DPreoperative and Intraoperative Predictors of
Coronary Artery Bypass Grafting Outcome
Although preoperative predictors can be used to counsel
patients and their relatives about the risks of surgery,
intraoperative predictors may influence decisions about
postoperative surveillance and treatments. Therefore, we
evaluated candidate predictors considering bothFIGURE 3. Adjusted association between PVD and primary composite
end point. The estimated event rates for patients with and without a history
of PVD are presented, assuming an age of 66 years, no history of HF, and
aspirin before CABG. The risk of the composite outcome was greater in
patients with PVD.
The Journal of Thoracic and Carpreoperative variables previously identified as significant
predictors and intraoperative variables, which are listed in
Table E2. The results of this analysis are presented in
Table 5. In addition to the 4 factors identified as preopera-
tive predictors, the intraoperative factor identified was the
duration of the cardiopulmonary bypass.Factors Not Predictive in the Multivariable Model
Many factors that were previously predictive of CABG
outcomes were no longer predictive in this recent cohort
(Table E3). Previous PCI was not a univariate predictor of
the composite end point (P ¼ .634), but previous CABG
was a univariate predictor (P ¼ .036). Neither previous
PCI nor previous CABG was an independent predictor.
Patients with a history of preoperative CVD (35% of the
population) had a trend toward a higher incidence of the
composite end point (5.91%) compared with those who
did not have CVD (4.41%,P¼ .063 by univariate analysis).
However, a history of CVD was not as predictive as PVD
and was not statistically significant in the multivariable
model of the composite end point. Histories of hyperten-
sion, hyperlipidemia, diabetes, and smoking were frequent
in this CABG population, but did not contributeTABLE 2. Death at postoperative day 28: Independent predictors of
all-cause mortality to day 28
Analysis of maximum likelihood estimates
Parameter Odds ratio
95%Wald
confidence limits P value
History of HF 1.929 1.022 3.641 .0428
Age (per 10-y increase) 1.034 1.002 1.067 .0353
History of PVD 1.724 0.954 3.118 .0714
Aspirin before CABG 0.316 0.176 0.566 .0001
CABG, Coronary artery bypass grafting; HF, heart failure; PVD, peripheral vascular
disease.
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TABLE 3. Stroke at postoperative day 28: Independent predictors of
stroke to day 28
Analysis of maximum likelihood estimates
Parameter Odds ratio
95%Wald
confidence limits P value
History of HF 1.288 0.621 2.672 .4966
Age (per 10-y increase) 1.036 1.003 1.070 .0308
History of PVD 1.926 1.058 3.504 .0320
Aspirin before CABG 0.855 0.382 1.915 .7032
CABG, Coronary artery bypass grafting; HF, heart failure; PVD, peripheral vascular
disease.
TABLE 5. Independent predictors of composite outcome including
preoperative and intraoperative variables
Analysis of maximum likelihood estimates
Parameter Odds ratio
95%Wald
confidence limits P value
History of HF 2.731 1.871 3.986 <.0001
Duration of CPB 1.774 1.460 2.156 <.0001
Age (per 10-y increase) 1.039 1.019 1.059 .0001
Aspirin before CABG 0.445 0.288 0.686 .0002
History of PVD 1.677 1.147 2.451 .0076
CABG, Coronary artery bypass grafting; HF, heart failure; PVD, peripheral vascular
disease; CPB, cardiopulmonary bypass.
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Dsignificantly to the final model. Preoperative atrial fibrilla-
tion was more common among patients who experienced
the composite outcome (13%) compared with those who
did not (8%, P¼ .018), but that history was not an indepen-
dent predictor. In some patients, atrial fibrillation may have
been a late manifestation of HF with cardiac dilatation.
Preoperative anemia (Hgb<11 or Hct<33) was found in
16% of the patients, and the anemic patients had a higher
proportion of the composite outcome, 7.4% (33/445
patients) compared with 4.6% for the nonanemic patients
(118/2297, P ¼ .016).
Potentially important predictors of outcome that were not
in the final models included not only preoperative anemia
but also intraoperative Hgb concentrations and transfusions
(Table E3), and none were independently predictive of
outcomes. A variety of myocardial protection techniques
were used, but none of the alternative approaches indepen-
dently influenced the outcomes.DISCUSSION
This report documents the risk factors predictive of
adverse events in a large contemporary multinational series
of patients undergoing CABG from the RED-CABG trial.
The 4 independent preoperative predictors of the composite
end point (at 28 days: death, nonfatal stroke, and SLVD)
were (1) a history of HF; (2) age; (3) a history of PVD;
and (4) not receiving aspirin before CABG. Many of the
risk factors that were important in previous eras of CABG
surgery were no longer significant in this contemporary
report. A remarkable finding was the low rates of mortalityTABLE 4. Severe left ventricular dysfunction at postoperative day 28:
Independent predictors of need for mechanical support for severe left
ventricular dysfunction to day 28
Parameter Odds ratio
95%Wald
confidence limits P value
History of HF 6.470 3.969 10.547 <.0001
Age (per 10-y increase) 1.013 0.985 1.041 .3731
History of PVD 1.043 0.577 1.883 .8903
Aspirin before CABG 0.478 0.260 0.881 .0181
CABG, Coronary artery bypass grafting; HF, heart failure; PVD, peripheral vascular
disease.
2724 The Journal of Thoracic and Cardiovascular Surand morbid events, which were consistent across the
contributing sites. Careful attention to these preoperative
risk factors may identify methods to further reduce the risks
of CABG. Awareness of these risk factors may alter
perioperative approaches, such as ensuring that nearly all
patients receive preoperative aspirin. We also evaluated
intraoperative variables and found that prolonged bypass
time was predictive of more postoperative complications.
Efforts to avoid complications that extend bypass duration
may improve outcomes.
In this study, HF but not EF was an independent risk
factor for adverse outcomes. Patients with HF but preserved
systolic function are increasingly recognized as high risk
for morbidity and mortality with revascularization,9,10 but
the influence of this condition on the outcomes of CABG
has been infrequently described. Hypertensive and
diabetic patients have a greater prevalence of HF despite
preservation of systolic function, and dyspnea or fatigue
may result from left ventricular diastolic dysfunction.10
Therefore, cardiac surgeons should pay particular attention
to patients with HF with preserved systolic function.
Careful preoperative assessment may identify the underly-
ing cardiac diastolic dysfunction and pulmonary, endocrine,
or renal abnormalities that would permit interventions to
mitigate this important risk factor. Attention to meticulous
myocardial protection and expeditious operations may
improve outcomes in this population. Reducing the
intraoperative crystalloid load may reduce early post-
operative cardiac edema and improve outcomes in these pa-
tients.11,12 Incomplete protection and prolonged procedures
increase postoperative cardiac edema,11,12 which could
exacerbate diastolic dysfunction and increase the risks of
postoperative adverse events.
The increasing age of those presenting for CABG3,7
mirrors the aging population, which is anticipated to
continue to increase in the next decade. The reasons for
the increased risk in older patients have not been fully
elucidated, but stem cell dysfunction in older patients
undergoing CABG may contribute to their limited healing
capacity.13,14 The recent National Institutes of Health
Effectiveness of Stem Cell Treatment for Adults Withgery c December 2014
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DIschemic Cardiomyopathy (the FOCUS Study) by the
Cardiovascular Cell Therapy Research Network (CCTRN)
trial15 documented the bone marrow (BM) stem cell
dysfunction in older patients with poor ventricular function
after an MI. The number of patients with active BM stem
cells was found to decrease with increasing age, but some
elderly patients had active BM stem cells and some younger
patients did not.16,17 In the near future, we may be able to
identify patients who have stem cell dysfunction and
rejuvenate their BM stem cells to restore their reparative
capacity.13,14,16,17
The increased risk in those who did not receive aspirin
preoperatively has been reported. In a prospective
placebo-controlled randomized trial of preoperative aspirin,
Deja and colleagues18 followed patients for up to 6 years
after CABG and found that preoperative aspirin decreased
both the risk of a major cardiac events (MI or repeated
revascularization, P ¼ .046) and the composite of death,
MI, or revascularization (P ¼ .06). Bybee and colleagues19
retrospectively reviewed 1636 patients undergoing primary
CABG and reported that preoperative aspirin reduced the
hospital mortality (P ¼ .007) without increasing the risk
of bleeding. Mangano20 reported that aspirin administration
before or within 48 hours after revascularization surgery
was associated with a 68% reduction in overall mortality
and substantially reduced the rates of ischemic complica-
tions in the heart (44% reduction in fatal and nonfatal MI
or congestive HF), the brain (62% reduction in fatal and
nonfatal stroke or encephalopathy), the kidneys (60%
reduction in renal dysfunction or failure), and the intestines
(70% reduction in ischemia or infarction). Therefore, the
benefits of preoperative and early postoperative aspirin
are well supported.
Previous studies documented the detrimental influence of
PVD on CABG outcomes. Both the Syntax Trial21 and the
study by Algarni and colleagues3 found that PVD was an
independent predictor of adverse long-term outcomes after
CABG. In addition to mortality, patients with an extensive
atherosclerotic burden have an increased risk of stroke,
perhaps because aortic atherosclerosis is a source for
cerebral emboli.22 PVD, and not a history of CVD, was
an independent determinant of stroke, perhaps because
patients with CVD had preoperative interventions (eg,
carotid stenting or carotid endarterectomy surgery) or
received careful intraoperative monitoring (including
increased perfusion pressures on bypass), which may have
reduced their risk of stroke with CABG.23 However,
patients with extensive aortic atherosclerosis have an
increased risk of stroke with any surgical approach that
requires aortic manipulation.22
Prolonged CPB time has been reported to correlate with
adverse outcomes.3,7 Reasons for prolonged CPB times
include operator facility, intraoperative problems with
diffuse coronary disease that may strain the capability ofThe Journal of Thoracic and Carmyocardial protection, bleeding due to tissue disruption,
or early ventricular dysfunction requiring multiple
interventions before separation from the bypass circuit.
Extended efforts to control bleeding or repair disrupted
friable tissues may be associated with adverse outcomes.
Awareness of the adverse influence of prolonged CPB
duration may permit surgical teams to avoid time-
consuming complications.
The initial report of this trial indicated that the majority
of patients were within the highest 3 quintiles of the Society
of Thoracic Surgeons risk score. This report provides
additional risk prediction to that achieved with the Society
of Thoracic Surgeons calculator.
Predictors of CABG outcomes that were previously
important were not significant in this study because of the
limited power of the study or changes to current surgical
techniques. Preoperative anemia was previously reported
to increase the risk of CABG.24 This trial excluded patients
undergoing urgent CABG or within 5 days of an MI, and
these patients contributed to many of the anemic patients
in previous reports. In this series of mostly elective
but moderately high-risk patients, preoperative anemia,
intraoperative anemia, and the need for blood transfusions
were not independently predictive of outcomes.
A recent meta-analysis found that blood was superior to
crystalloid cardioplegia and that tepid was better than warm
blood cardioplegia in most randomized clinical trials.25
However, although bypass time was an independent predic-
tor, the type of myocardial protection was not significantly
associated with adverse outcomes. Either this study lacks
sufficient power to distinguish among the various cardiople-
gic combinations or cardiac surgeons have optimized their
approaches to myocardial protection and developed
permutations of temperature, composition, and delivery to
meet the needs of each individual patient, such that none
of the individual approaches are no longer predictive of
outcomes. Wewere surprised to find little regional variation
in the primary outcomes of the trial, and region was not a
univariable or multivariable predictor of any of the
outcomes studied. In addition, we did not find that diabetes
mellitus added to the early risk of adverse outcomes, similar
to the report of the FREEDOM Trial.4 Consistent with
recent reports, hypertension, hyperlipidemia, smoking,
and a history of atrial fibrillation did not influence early
outcomes of CABG, although these factors will have an
effect on intermediate- and long-term outcomes.1-4 Left
main stenosis, reoperative CABG, and previous PCI have
not been important predictors for many years.1-4,26
Study Limitations
A major limitation of this report is that the trial was
intended to evaluate the effects of acadesine and not to
determine the predictors of adverse outcomes. However,
the investigators initiated this substudy to use the extensivediovascular Surgery c Volume 148, Number 6 2725
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Ddata collected in this large trial. Another limitation of the
current study is the lack of inclusion of patient populations
commonly seen by cardiac surgeons, including those under-
going combined valve and CABG surgery, and those with
recent MI. However, the uniform patient characteristics
and large multinational patient population provide current
predictors and permit the identification of interventions to
modify adverse outcomes.CONCLUSIONS
This study provides a snapshot of the predictors of
adverse outcomes in a large contemporary cohort of
patients undergoing CABG. The independent preoperative
predictors of adverse outcome were preexisting HF, PVD,
advancing age, and no preoperative aspirin. As anticipated,
age and PVD predicted stroke, whereas a history of HF
predicted SLVD. This information identifies new targets
for quality improvement that may further reduce the risks
of CABG surgery.References
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TABLE E1. Baseline characteristics
Characteristic N ¼ 3080
Age, y
Mean (SD) 66.5 (8.6)








Mean (SD) 86.5 (19.5)
Median (IQR) 85.0 (73.0-98.0)





The Netherlands 13 (0.4)
Spain 75 (2.4)
United States 1986 (64.5)
Cardiovascular history, no. (%)
Hypertension 2727 (88.6)
History of cigarette smoking 1916 (62.3)
Hyperlipidemia 2656 (86.3)
Diabetes mellitus 1866 (60.6)
Family history of CAD 1143 (49.0)
Prior MI 1487 (48.4)
Prior angina 1696 (55.1)
Prior stroke 302 (9.8)
Prior transient ischemic attack 186 (6.0)
Prior known carotid stenosis 50% 373 (12.1)
Other CVD 53 (1.7)
Prior PVD 483 (15.7)
Claudication 278 (9.0)
HF 408 (13.3)
History/presence of AF or atrial flutter 251 (8.2)
Prior PCI 803 (26.1)
Prior CABG surgery 153 (5.0)
Prior percutaneous carotid intervention 43 (1.4)




AF, Atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery
disease; CVD, cerebrovascular disease; HF, heart failure; IQR, interquartile range;
MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral
vascular disease; SD, standard deviation.
TABLE E2. Intraoperative univariate predictors of the composite end










Last Hct before CABG end 0.0172 0.2709 0.0187 0.9012
Last Hgb before CABG end 0.0217 0.0301 0.3501 0.4591
Transfusion 0.0723 0.3065 0.1469 0.0002
Cardioplegia type 0.2771 0.4315 0.8504 0.7492
Cardioplegia temperature 0.2232 0.7941 0.2543 0.1638
Cardioplegia delivery method 0.2975 0.5373 0.9139 0.0262
No. of venous grafts 0.9651 0.4408 0.4583 0.0455
No. of arterial grafts 0.5038 0.9096 0.8060 0.0732
Duration of crossclamp (h) 0.1890 0.1172 0.5542 0.0139
Duration of CPB (h) <0.0001 <0.0001 0.6084 <0.0001
Atrial fibrillation before
CABG end, per ECG
0.0112 0.1199 0.4285 0.2348
The final model included 5 covariates and had a C-index of C¼ 0.696 (better than the
preoperative model, which had a C-Index of 0.66) based on N ¼ 2897 observations.
The Hosmer–Lemeshow test for lack of fit was nonsignificant (chi-square ¼ 4.98,
P ¼ .76). CABG, Coronary artery bypass grafting; CPB, cardiopulmonary bypass;
ECG, electrocardiogram; Hct, hematocrit; Hgb, hemoglobin; NF, nonfatal;
SLVD, severe left ventricular dysfunction.











Age at randomization 0.0005 0.0219 0.0237 0.2605
Male gender 0.0352 0.0220 0.8985 0.3458
EF 0.0001 0.0512 0.7071 <0.0001
No. of diseased vessels 0.3767 0.6327 0.7616 0.0398
LMT>50% stenosis 0.4494 0.2920 0.5172 0.2027
Evidence of preoperative
CVD
0.0639 0.1760 0.0168 0.6818
History of PVD 0.0022 0.0425 0.0216 0.4597
Prior PCI 0.6341 0.1901 0.6108 0.9869
Prior CABG 0.0390 0.1778 0.7037 0.0030
Prior HF <0.0001 0.0321 0.3919 <0.0001
Prior MI 0.6951 0.8119 0.6302 0.1111
Hypertension 0.5646 0.3165 0.4013 0.4131
Hyperlipidemia 0.7015 0.0366 0.6724 0.9032
Diabetes 0.8224 0.9903 0.1234 0.2254
Smoking 0.3052 0.0576 0.9178 0.6262
Prior atrial fibrillation 0.0201 0.0352 0.1622 0.8653
Aspirin before CABG 0.0012 <0.0001 0.6592 0.0230
Clopidogrel before CABG 0.6031 0.6161 0.3835 0.7100
Anemia before CABG 0.0168 0.0893 0.2377 0.3693
The final preoperative model had a C-index of 0.66, and the discrimination slope for
the model was 0.029. Hosmer–Lemeshow chi-square ¼ 7.78, P ¼ .46. CABG,
Coronary artery bypass grafting; CVD, cerebrovascular disease; EF, ejection fraction;
HF, heart failure; LMT, left main trunk; MI, myocardial infarction; NF, nonfatal;
PCI, percutaneous coronary intervention; PVD, peripheral vascular disease;
SLVD, severe left ventricular dysfunction.
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